CSL – Deutsche Bank rates the stock as Hold

By Broker News | More Articles by Broker News

Deutsche Bank notes from the company’s R&D briefing that CSL believes the development of anti-FcRn drugs will have a place in simple autoimmune disease but is not convinced of the long-term safety issues. 

Ig also has a faster treatment effect on simple autoimmune disease, such as Immune Thrombocytopenia. CSL is currently developing a recombinant Fc multimer which may help with replacing volumes of Ig lost to anti-FcRn drugs. Hold retained. Target is $207.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $207.00.Current Price is $179.24. Difference: $27.76 – (brackets indicate current price is over target). If CSL meets the Deutsche Bank target it will return approximately 13% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →